A new antibiotic approved by the FDA Thursday will give doctors another option against tough acting infections.

Tygacil, known chemically as tigecycline, is an intravenous antibiotic, for use in treating complicated abdominal and skin infections in adults

McNeil Consumer & Specialty Pharmaceuticals, a unit of health care products company Johnson & Johnson Inc., is recalling certain lots of Children's Tylenol because of confusing packaging that could result in overdosing. The company announced the recall Friday of all lots and all flavors of 80 milligram-strength Children's Tylenol Meltaways packaged in bottles and blisters, 80 milligram-strength Children's Tylenol SoftChews packaged in blisters, and 160 milligram-strength Jr. Tylenol Meltaways packaged in blisters - affecting only SoftChews and Meltaways versions of the product. Taking more than the prescribed dosage of acetaminophen, the active ingredient in Tylenol, may cause liver damage when taken for three or more days. In 80 milligram-strength products, the recall was triggered by concerns that blister packs containing two pills in each compartment would lead some consumers to believe that the two tablets contained a total of 80 milligrams of acetaminophen, when the tablets actually contain 80 milligrams each. According to CBS News, McNeil spokeswoman Kathy Fallon said in an interview that the company eliminated the double-pill blister cavity design for a single pill cavity design in the first quarter. As for bottled products and the 160 milligram-strength product, the company said that labeling on the front panel of the carton could confuse consumers on proper dosages. The spokeswoman said that McNeil was changing wording on the front of the package to say that each "tablet" contains the given strength of acetaminophen rather than each "dose." According to Fallon's statement, it was consumer complaints alerted rhe company to the possible confusion.

The report states that the company has notified the Food and Drug Administration of the voluntary recall and that it will launch a campaign to alert consumers about proper dosages

San Diego biotech company, Arena Pharmaceuticals, says an experimental anti-obesity drug called ADP356 has done well in small clinical Phase II trials.

The drub, when taken at it's highest dose enabled obese people to lose an average of 2.9 pounds after 28 days, compared with just 0.7 pounds for those getting a placebo

A new diabetes treatment will be based on saliva from a Gila monster, AP reports. The drug, named Byetta, manufactured by Amylin Pharmaceuticals and Eli Lilly & Co., has just cleared FDA testing. Reports say it will hit the market June 1.

According to the makers, "Byetta is a synthetic version of a protein found in the saliva of the Gila monster that works similarly to the human GLP-1

The Food and Drug Administration annouced its approval of a new drug derived from the saliva of a poisonous lizard called the Gila monster.

Byetta, chemically called exenatide, is the newest option for Type 2 diabetics. The drug is the first of its kind, requires injections twice a day, and presently must be taken along with older diabetes treaments